Abstract:Background Pembrolizumab has robust antitumor activity in advanced melanoma and has been approved for the treatment of melanoma in many countries. Adjuvant pembrolizumab was associated with longer recurrence-free survival (RFS) in patients with resected stage III melanoma. We herein report on the RFS outcomes of Chinese patients with resected stage III melanoma receiving adjuvant pembrolizumab in comparison to those receiving interferon alpha-2b (IFN-alpha-2b). Methods We retrospectively investigated the medical records of subjects with resected stage III melanoma with no in-transit metastases diagnosed who were treated at the Cancer Hospital of the University of Chinese Academy of Sciences and collected historical clinical data of patients receiving adjuvant IFN-alpha-2b therapy in our hospital. The RFS rates were evaluated using Kaplan-Meier curves, and the differences between the groups were tested using the log-rank test. Results A total of 29 patients receiving adjuvant pembrolizumab therapy and 27 patients receiving adjuvant IFN-alpha-2b therapy were enrolled. The median RFS was not reached (95% CI not estimable [NE]) in the pembrolizumab group and was 25 months in the IFN-alpha-2b group, and there was no significant difference in RFS between the pembrolizumab and IFN-alpha-2b groups (HR = 1.20, log-rank p = 0.75). There was no significant difference in RFS for acral melanoma between the pembrolizumab group and IFN-alpha-2b group (HR = 1.22, log-rank p = 0.79). For patients with IIIC or IIID melanoma, the RFS in the pembrolizumab group was also similar to that of the IFN-alpha-2b group (HR = 0.80, log-rank p = 0.47). The RFS for patients receiving pembrolizumab with programmed cell death ligand 1 (PD-L1)-positive tumors might tend to be longer than that for patients with PD-L1-negative tumors, but there was no significant difference between the groups (HR = 3.37, log-rank p = 0.17). High tumor mutational burden (TMB) did not reveal a trend to predict a longer RFS than low TMB in patients receiving pembrolizumab (HR = 1.63, log-rank p = 0.63). Grade 3-4 adverse events occurred in 6 (22.22%) of 27 patients in the IFN-alpha-2b group. Discontinuations attributed to adverse events (AEs) occurred in 2 patients treated with IFN-alpha-2b. Immune-related adverse events were observed in 5 (17.24%) patients in the pembrolizumab group. In the pembrolizumab group, grade 3-4 adverse events occurred in 2 (6.90%) patients, 1 of which required the discontinuation of a study drug and corticosteroid treatment. None of the patients discontinued treatment due to treatment-related or immune-mediated AEs. Conclusions Adjuvant pembrolizumab appeared to be as effective as IFN-alpha-2b in prolonging RFS in Chinese patients with resected stage III melanoma. Adjuvant pembrolizumab was associated with a lower rate of treatment-related AEs than IFN-alpha-2b. A prospective study is needed to confirm the clinical benefit of adjuvant pembrolizumab and determine dependable biomarkers.

Association of Immune-Inflammation Index with Outcome of High-Risk Acral Melanoma Patients Treated with Adjuvant High-Dose Interferon.

Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon

A Randomised Phase II Trial of 1month Versus 1year of Adjuvant High-Dose Interferon Α-2B in High-Risk Acral Melanoma Patients

The Predictive Significance of the Advanced Lung Cancer Inflammation Index (ALI) in Patients with Melanoma Treated with Immunotherapy as Second-Line Therapy

A Randomized Phase Ii Trial of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in High-Risk Acral Melanoma Patients.

Intravenous High-Dose Interferon With Or Without Maintenance Treatment In Melanoma At High Risk Of Recurrence: Meta-Analysis Of Three Trials

Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment

Impact of Interferon-alpha1b (IFN-α1b) on Antitumor Immune Response: An Interpretation of the Promising Therapeutic Effect of IFN-alpha1b on Melanoma

Tolerability of Patients with Maliguant Melanoma to Induction Phase of Adjuvant High-dose Interferon Therapy

Adjuvant Pembrolizumab Versus High-Dose Interferon Α-2B for Chinese Patients with Resected Stage III Melanoma: a Retrospective Cohort Study.

Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients

Phase Ii Randomized Study of High-Dose Interferon Alfa-2b (hdi) Versus Chemotherapy As Adjuvant Therapy in Patients with Resected Mucosal Melanoma

The established of a machine learning model for predicting the efficacy of adjuvant interferon alpha1b in patients with advanced melanoma

Association between systemic immune inflammation index and short term prognosis of acute on chronic liver failure

The Low Systemic Immune-inflammation Index predicts Poor Outcome and Early Recurrence in High-risk Patients with Pancreatic Head Cancer Undergoing Pancreaticoduodenectomy

Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors

An immune risk score predicts progression-free survival of melanoma patients in South China receiving anti-PD-1 inhibitor therapy—a retrospective cohort study examining 66 circulating immune cell subsets

Systemic Immune-In Fl Ammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma

Prognostic implications of systemic immune-inflammation index in patients with bone metastases from hepatocellular carcinoma treated with radiotherapy

[Effect of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer and chronic obstructive pulmonary disease]

Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684